{"id":2327,"date":"2017-07-12T12:17:44","date_gmt":"2017-07-12T12:17:44","guid":{"rendered":"http:\/\/www.cardiolinkgroup.com\/xenios-la-mejor-proteccion-pulmonar\/"},"modified":"2017-07-12T12:21:43","modified_gmt":"2017-07-12T12:21:43","slug":"xenios-la-mejor-proteccion-pulmonar","status":"publish","type":"post","link":"https:\/\/www.cardiolinkgroup.com\/en\/xenios-la-mejor-proteccion-pulmonar\/","title":{"rendered":"Xenios: The best lung protection"},"content":{"rendered":"

“Venovenous extracorporeal membrane oxygenation (ECMO) is a rescue therapy in the treatment of refractory respiratory failure that improves oxygenation, reduces CO2 and facilitates the application of protective MV, potentially reducing MV-associated lung injury. “<\/span><\/strong><\/p>\n

(http:\/\/medintensiva.org\/es\/ventilacion-mecanica-pacientes-tratados-con\/avance\/S0210569117300062\/)<\/h5>\n

Currently, it could be said that the benefits of ECMO in patients with pulmonary pathologies are becoming more and more evident and are very well documented. That is why, at Cardiolink we fully rely on the best technology to be able to offer patients an early recovery in the fastest and most efficient way. <\/span><\/p>\n

Our main objective is to achieve a protective lung ventilation thanks to the XENIOS platform technology: the latest generation solution for the minimally invasive treatment of acute and chronic pulmonary insufficiency. Their concept of lung protection is based on the fact that “mechanical ventilation is life-saving therapy, but it can also kill the lung.” Because positive pressure ventilation is never physiological, being intubated and connected to a mechanical ventilator involves multiple pathophysiological processes that may cause additional lung damage (VALI \/ VILI).<\/span><\/p>\n

Under mechanical ventilation, the respiratory muscles begin to degenerate in a very short time (Ventilator-Induced Diaphragmatic Dysfunction, VIDD), so that intubation prevention is the only protection against ventilation-induced lung damage. Hence, the purpose of Xenios is to maintain tension in the lungs during connection to VM as low as possible in order to achieve pulmonary protection ventilation<\/strong>.<\/span><\/p>\n

Novalung products can replace or reduce invasive mechanical ventilation with therapies tailored to the needs of each patient. The Novalung platform performs any level of CO2 elimination and oxygenation in acute respiratory failure \/ COPD.<\/span><\/p>\n

The iLA<\/strong> therapies provide relief to the respiratory system, allowing reduction of respiratory parameters (tidal volume, respiratory rate and respiratory pressure). The oxygenation membrane “breathes” by the patient in an extracorporeal way, thus helping the lung in the gas exchange.<\/span><\/p>\n

This allows for earlier lung recovery since extracorporeal CO2 elimination, which reduces the need for mechanical ventilation in the patient, can potentially prevent the side effects of mechanical ventilation. Therefore, applying ECMO therapy in respiratory distress, in addition to providing immediate oxygen support in hypoxemic and \/ or acidotic patients, provides the ideal lung protection so that the patient can recover as soon as possible.<\/span><\/p>\n

If you have not yet tested the effectiveness of Xenios, do not wait any longer and consult us for a demonstration!<\/span><\/p>","protected":false},"excerpt":{"rendered":"

“Venovenous extracorporeal membrane oxygenation (ECMO) is a rescue therapy in the treatment of refractory respiratory failure that improves oxygenation, reduces CO2 and facilitates the application of protective MV, potentially reducing MV-associated lung injury. “ (http:\/\/medintensiva.org\/es\/ventilacion-mecanica-pacientes-tratados-con\/avance\/S0210569117300062\/) Currently, it could be said that the benefits of ECMO in patients with pulmonary pathologies are becoming more and more […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[96,90],"tags":[83,91,102,317,105,318,319,320,321,322,109,323],"class_list":["post-2327","post","type-post","status-publish","format-standard","hentry","category-icu","category-cardiolink-en","tag-cardiolink-en","tag-cardiolink-group-en","tag-ecmo-en","tag-ila-en","tag-novalung-en","tag-oxigenacion-en","tag-proteccion-pulmonar-en","tag-tratamiento-pulmonar-en","tag-ventilacion-protectora-en","tag-ventilacion-pulmonar-en","tag-xenios-en","tag-xenios-ag-en"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t